InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Combs Andrew, Executive. Director active across 1 company, notably Prelude Therapeutics Inc. Cumulatively, 3 reports have been logged. Split: 2 buys · 0 sell. Total volume traded: €86k. Activity tracked since 13 December 2021. The latest transaction was filed on 31 March 2022 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations3 total
36,062 shares@ US$1.890.017% mcap41.8% of flowCommon StockSEC:0001209191-22-022524:0
4,000 shares@ US$12.120.012% mcap100.0% of flowCommon StockSEC:0001209191-21-069796
Ideal exit: 9 Sept 2022 (T+270)
4,000 shares@ US$12.120.012% mcap29.1% of flowCommon StockSEC:0001209191-21-069796:0
Ideal exit: 9 Sept 2022 (T+270)
3 of 3 declarations
About Combs Andrew
Andrew Combs is Executive Vice President and Head of Chemistry at Prelude Therapeutics Inc. He oversees the company's research and development initiatives, focusing on innovation in the therapeutic area.
